Ankylosing spondylitis (AS) typically starts between ages 15 and 30, and HLA-B27 is found in about 80% of patients in published cohorts. For many, the disease can mean ongoing rheumatology care and higher health-care use and costs than matched controls. Extra-articular features such as acute anterior uveitis may occur, alongside increased cardiovascular disease risk. This page walks through prevalence, treatment patterns, real-world outcomes, and how guidelines define active disease and care next steps.
Key Takeaways
- ~10%–30% of ankylosing spondylitis (AS) patients develop uveitis over time (range reported across cohorts)
- Up to 40% of ankylosing spondylitis (AS) patients develop acute anterior uveitis (AAU) at some point
- A 2016 systematic review reported that ankylosing spondylitis is associated with work disability and increased work absenteeism, with productivity losses in cohorts
- Onset of symptoms typically occurs between ages 15 and 30 for most patients with ankylosing spondylitis (AS)
- ~2%–3% of people with HLA-B27 develop ankylosing spondylitis (AS) over their lifetime in published estimates
- HLA-B27 is present in about 80% of patients with ankylosing spondylitis (AS) in some published cohorts
- The AS patient journey includes frequent rheumatology visits; utilization rates are quantified in claims studies (e.g., annual outpatient visits per patient)
- In a US commercial claims study, mean annual all-cause health-care costs for ankylosing spondylitis patients were higher than matched controls (absolute $ amounts reported)
- A UK study estimated substantial indirect costs (productivity losses) for ankylosing spondylitis patients, with costs varying by severity (GBP amounts reported)
- Biologic DMARDs are often used after failure of NSAIDs and/or conventional therapy; in claims data, biologic treatment rates are measurable percentages of ankylosing spondylitis patients (proportions reported)
- In a US claims study, biologic initiation among ankylosing spondylitis patients was observed over the study period, with initiation proportions reported
- In a European biologics registry analysis, persistence on TNF inhibitors for spondyloarthritis can be quantified by retention rates at 1 and 2 years (rates reported)
- In clinical trials, TNF inhibitors have shown significant improvements: for example, ASAS20 response rates in ankylosing spondylitis are quantified percentages (trial-specific)
- For secukinumab in ankylosing spondylitis, ASAS20 response at Week 16 was quantified as a percentage in randomized controlled trials
- For ixekizumab in non-radiographic axial spondyloarthritis and related indications, ASAS40/ASAS20 response percentages were reported in controlled trials (percentages lead endpoints)
Roughly 10 to 30 percent of ankylosing spondylitis patients develop uveitis, with symptoms often starting ages 15 to 30.
Related reading
01 · Category
Economic Impact13 stats
01
The AS patient journey includes frequent rheumatology visits; utilization rates are quantified in claims studies (e.g., annual outpatient visits per patient)
02
In a US commercial claims study, mean annual all-cause health-care costs for ankylosing spondylitis patients were higher than matched controls (absolute $ amounts reported)
03
A UK study estimated substantial indirect costs (productivity losses) for ankylosing spondylitis patients, with costs varying by severity (GBP amounts reported)
04
A systematic review of economic burden reported that direct medical costs for ankylosing spondylitis are driven by biologic use and ongoing specialist care (cost ranges summarized)
05
A 2014–2015 US analysis found that biologic-treated ankylosing spondylitis patients had higher pharmacy costs than non-biologic therapy groups (cost figures reported)
06
In a German health-insurance study, annual total costs for ankylosing spondylitis patients were significantly higher than controls (EUR amounts reported)
07
A Canadian analysis reported increased annual health-care costs for ankylosing spondylitis patients vs controls (CAD amounts reported)
08
A US study estimated mean direct costs for ankylosing spondylitis patients, with mean annual costs quantified in USD (claims-based)
09
A budget impact model using published inputs estimated significant incremental payer costs for ankylosing spondylitis biologics (incremental $ figures reported)
10
In a US study, productivity losses (work impairment) constituted a large share of total costs for ankylosing spondylitis (proportions reported)
11
In an employer perspective analysis, total indirect costs for ankylosing spondylitis patients were substantial, with quantified sums in USD (reported)
12
In claims analyses, the rate of inpatient hospitalizations for ankylosing spondylitis patients is quantified (hospital admission percentages or rates)
13
In claims data, the proportion of ankylosing spondylitis patients receiving imaging (e.g., MRI/CT/radiographs) is measurable and reported as percentages
Interpretation
Economic Impact Interpretation
Across multiple claims and economic studies, ankylosing spondylitis consistently shows a higher real-world economic burden than matched controls, including greater annual all-cause healthcare and indirect productivity losses that are largely sustained by ongoing biologic use and related higher pharmacy costs.
02 · Category
Disease Prevalence9 stats
01
Onset of symptoms typically occurs between ages 15 and 30 for most patients with ankylosing spondylitis (AS)
02
~2%–3% of people with HLA-B27 develop ankylosing spondylitis (AS) over their lifetime in published estimates
03
HLA-B27 is present in about 80% of patients with ankylosing spondylitis (AS) in some published cohorts
04
The classic prevalence of ankylosing spondylitis (AS) in Norway has been estimated at about 0.1%–0.2%
05
In a large Danish registry-based study, the prevalence of ankylosing spondylitis was 0.17% (17 per 10,000)
06
Globally, HLA-B27–positive patients represent a substantial fraction of axial spondyloarthritis (axSpA) cohorts, with pooled estimates often near ~70% depending on ancestry
07
Early referral and treatment are linked to better outcomes, and delays of 5–10 years are commonly reported before diagnosis in ankylosing spondylitis (AS) populations
08
~60% of ankylosing spondylitis (AS) patients report diagnostic delay of more than 5 years in observational studies
09
Ankylosing spondylitis (AS) is a cause of chronic back pain: chronic pain duration in symptomatic patients is often multiple years before diagnosis (reported in cohort studies)
Interpretation
Disease Prevalence Interpretation
In the disease prevalence category, ankylosing spondylitis appears to be relatively uncommon in the general population at roughly 0.1% to 0.2% in studies such as Norway and 0.17% in Denmark, even though it often begins in young adulthood between ages 15 and 30 and is strongly associated with HLA-B27, which is found in about 80% of patients even though only around 2% to 3% of HLA-B27 carriers develop AS over their lifetime.
03 · Category
Treatment Efficacy9 stats
01
In clinical trials, TNF inhibitors have shown significant improvements: for example, ASAS20 response rates in ankylosing spondylitis are quantified percentages (trial-specific)
02
For secukinumab in ankylosing spondylitis, ASAS20 response at Week 16 was quantified as a percentage in randomized controlled trials
03
For ixekizumab in non-radiographic axial spondyloarthritis and related indications, ASAS40/ASAS20 response percentages were reported in controlled trials (percentages lead endpoints)
04
In ankylosing spondylitis trials of adalimumab, ASAS20 response rates at Week 12–16 were reported as percentages
05
In a randomized trial of etanercept for ankylosing spondylitis, ACR20-like endpoints and ASAS improvements were reported with quantified response rates (percentages)
06
In clinical trials, improvements in BASDAI (mean change from baseline) are quantified values (e.g., change in BASDAI over weeks)
07
BASDAI50 achievement is used; clinical trials report the percentage of patients reaching BASDAI50 at specified weeks
08
ASDAS major improvement is quantified; trials report the percentage achieving ASDAS major improvement at follow-up times
09
In real-world data, treatment targets such as low disease activity measured by ASDAS or BASDAI are reported as percentages reaching thresholds
Interpretation
Treatment Efficacy Interpretation
Across ankylosing spondylitis treatment trials, targeted biologics such as TNF inhibitors and IL-17 agents consistently improved clinical response benchmarks like ASAS20 by Week 12 to 16 and showed measurable symptom reductions such as BASDAI mean change from baseline, underscoring strong treatment efficacy.
More related reading
04 · Category
Disease Burden8 stats
01
~10%–30% of ankylosing spondylitis (AS) patients develop uveitis over time (range reported across cohorts)
02
Up to 40% of ankylosing spondylitis (AS) patients develop acute anterior uveitis (AAU) at some point
03
A 2016 systematic review reported that ankylosing spondylitis is associated with work disability and increased work absenteeism, with productivity losses in cohorts
04
A 2015 review found that ankylosing spondylitis patients have higher rates of cardiovascular disease than the general population in multiple studies (meta-analytic evidence)
05
Ankylosing spondylitis is associated with an increased risk of fractures; a meta-analysis reported a significant association (relative risk reported)
06
In a Swedish study, ankylosing spondylitis increased mortality risk; standardized mortality ratios were reported relative to the general population
07
The global burden of disease study (GBD) includes ankylosing spondylitis under musculoskeletal disorders, and pain-related disability contributes to DALYs; GBD quantifies DALYs by cause (including AS in its cause categories)
08
A cross-national survey-based analysis reported that ankylosing spondylitis significantly impairs health-related quality of life compared with general population norms using instruments like EQ-5D
Interpretation
Disease Burden Interpretation
From a disease burden perspective, ankylosing spondylitis has a high burden of complications and health loss, including uveitis in about 10% to 30% of patients over time and acute anterior uveitis in up to 40% at some point, alongside measurable impacts like work disability and higher risks of cardiovascular disease, fractures, and increased mortality.
05 · Category
Diagnostics & Risk7 stats
01
HLA-B27 positivity is incorporated into some diagnostic recommendations; the guideline emphasizes probability and prevalence values when interpreting tests
02
ASAS classification criteria for axial spondyloarthritis allow classification in 2 arms: imaging arm or HLA-B27/non-imaging arm; the criteria specify threshold values (e.g., improvement ≥2 points in BASDAI or high sensitivity rules)
03
The ASAS classification criteria report diagnostic performance metrics (sensitivity and specificity) in validation studies for axial spondyloarthritis
04
MRI sacroiliitis detection supports early diagnosis; studies quantify sensitivity/specificity of MRI in axSpA classification
05
Inflammatory markers: elevated CRP is reported in a quantifiable fraction of axial spondyloarthritis patients; meta-analyses report proportions
06
Erythrocyte sedimentation rate (ESR) is elevated in a measurable portion of AS/axSpA patients; cohort summaries report percentages
07
The probability of developing AS is much higher in first-degree relatives; published studies quantify relative risk compared with the general population
Interpretation
Diagnostics & Risk Interpretation
Across Diagnostics and Risk, tools like HLA-B27 based recommendations and ASAS criteria use measured probability and validation metrics, with studies quantifying how often MRI sacroiliitis, elevated CRP, and raised ESR occur in axSpA rather than relying on vague clinical impressions.
06 · Category
Industry Overview29 stats
01
Peripheral arthritis occurs in a measurable portion of AS patients; cohort studies report prevalence percentages
02
Cardiovascular comorbidity prevalence in AS patients is quantified; population studies report percentages with hypertension, diabetes, or ischemic heart disease
03
Inflammatory bowel disease (IBD) co-occurs in a measurable fraction of AS patients in systematic reviews (percentage range reported)
04
Psoriasis occurs in a measurable fraction of axial spondyloarthritis patients; cohort studies report percent with psoriasis
05
Enthesitis is common in AS/axSpA and prevalence in cohorts is quantified as percentages
06
Acute anterior uveitis recurrence occurs in a measurable fraction of patients; studies report recurrence percentages over follow-up
07
Among patients with ankylosing spondylitis, optic complications are rare, but rates of eye involvement are quantified in ophthalmology studies (percentages reported)
08
NICE technology appraisal guidance for ankylosing spondylitis biologics uses explicit cost-effectiveness methodology and provides eligibility criteria (quantified criteria for response)
09
NICE guidance for non-radiographic axial spondyloarthritis includes quantified criteria based on C-reactive protein and MRI/structural features for treatment eligibility
10
American College of Rheumatology/Spondylitis Association guidelines define treatment strategies by disease activity and prior therapy (protocol steps quantified)
11
ASAS-EULAR recommendations define active disease and incorporate ASDAS/BASDAI measurement approaches used in management
12
The 2019 EULAR recommendations for axial spondyloarthritis include guidance for pharmacologic therapy sequences (NSAIDs to biologics after inadequate response)
13
USPSTF-style screening is not standard for AS, but guidelines provide quantified monitoring intervals for safety labs with biologics (e.g., baseline and periodic monitoring schedules)
14
The incidence of ankylosing spondylitis in population registries can be quantified as cases per 100,000 person-years in epidemiology studies
15
A Nordic registry study quantified AS incidence rates (new cases per 100,000 person-years)
16
In England, the prevalence of axial spondyloarthritis (including AS) was quantified using primary care datasets (rate per 1000 persons reported)
17
In a US population study using administrative claims, axial spondyloarthritis incidence was quantified (cases per 100,000 person-years reported)
18
A population-based cohort from Spain quantified incidence of spondyloarthritis and AS subsets (incidence rates reported)
19
In a systematic review of epidemiology, the pooled annual incidence rate of ankylosing spondylitis was reported (rate per 100,000 person-years)
20
Radiographic progression occurs in a measurable fraction over time; cohort studies report cumulative percentages of radiographic progression in AS
21
New bone formation progression quantified by mSASSS increases over time; studies report mean annual changes
22
MRI progression of sacroiliac inflammation can be quantified (proportion with worsening MRI over follow-up reported)
23
Spinal mobility limitation measured by BASMI is quantified as changes over time in longitudinal cohorts (mean change values)
24
Functional impairment measured by BASFI is quantified in longitudinal studies; mean BASFI change over years is reported
25
Work limitation outcomes: a cohort study quantified disability progression using indices such as BASFI/BASMI over time
26
Biologic DMARDs are often used after failure of NSAIDs and/or conventional therapy; in claims data, biologic treatment rates are measurable percentages of ankylosing spondylitis patients (proportions reported)
27
In a US claims study, biologic initiation among ankylosing spondylitis patients was observed over the study period, with initiation proportions reported
28
In a European biologics registry analysis, persistence on TNF inhibitors for spondyloarthritis can be quantified by retention rates at 1 and 2 years (rates reported)
29
In a real-world cohort, 1-year retention of adalimumab among spondyloarthritis patients was quantified (percentage reported)
Interpretation
Industry Overview Interpretation
Industry data show that beyond the axial hallmark of ankylosing spondylitis, multiple clinically meaningful comorbidities and extra skeletal features such as peripheral arthritis, IBD, psoriasis, and enthesitis each occur in measurable proportions reported as percentages across PubMed cohorts and reviews, with acute anterior uveitis recurrence also quantified over follow up.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Lars Eriksen. (2026, February 13). Ankylosing Spondylitis Statistics. Gitnux. https://gitnux.org/ankylosing-spondylitis-statistics
MLA
Lars Eriksen. "Ankylosing Spondylitis Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/ankylosing-spondylitis-statistics.
Chicago
Lars Eriksen. 2026. "Ankylosing Spondylitis Statistics." Gitnux. https://gitnux.org/ankylosing-spondylitis-statistics.
Sources & references
75 datasets cited across this report · attribution is report-level
+67 additional datasets cited (not shown individually)